Prostate cancer is the most common solid-organ cancer affecting the male population.
Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-resistant state and until recently chemotherapy was the only treatment available with proven survival benefit. Abiraterone is a new class of anti-androgen with proven survival benefit post-chemotherapy. In this review we discuss the characteristics of abiraterone and the clinical trials that led to its approval for the treatment of patients with prostate cancer.
Written by:
Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M. Are you the author?
Department of Urology, Northampton General Hospital, Northampton, UK.
Reference: Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37.
doi: 10.1586/era.12.12
PubMed Abstract
PMID: 22500680
UroToday.com Prostate Cancer Section